Wockhardt, RDIF strike deal with for Sputnik V and Sputnik Light vaccines

TAGS

The Russian Direct Investment Fund (RDIF), the Russian sovereign wealth fund, has entered into a partnership with Indian pharma company Wockhardt Limited for producing and distributing the Sputnik V and Sputnik Light vaccines against .

The agreement was signed under the watch of , part of , which is the coordination partner of RDIF for procuring the Sputnik V vaccines in India.

— Chairman of Enso Healthcare said: “It is our privilege to partner with RDIF and Wockhardt to facilitate large scale manufacturing of Sputnik V and Sputnik Light vaccines. Vaccinations are the most visible solution to this pandemic.

See also  Mesoblast issues shares to Osiris Therapeutics after FDA approval of Ryoncil

“We are proud to be a part of this noble cause. Sputnik V is known to have high efficacy and has emerged as a trusted vaccine.”

Wockhardt, RDIF strike deal with for Sputnik V and Sputnik Light vaccines

Wockhardt, RDIF strike deal with for Sputnik V and Sputnik Light vaccines. Photo courtesy of The Russian Direct Investment Fund.

Sputnik V, which is based on human adenoviral vectors, uses two different vectors for the two vaccine shots. As a result, it is claimed to give immunity with a longer duration than other Covid vaccines using the same mechanism for the delivery of both shots.

See also  Elevation Oncology strengthens cancer drug pipeline as cash reserves hit $93m

On the other hand, Sputnik Light is the first component of the Sputnik V vaccine, and is based on human adenovirus serotype 26.

Dr. Habil Khorakiwala — Founder Chairman of Wockhardt Group said: “We are delighted to partner with RDIF to make a substantial contribution towards providing global supply of the Sputnik V and Sputnik Light vaccines which is one of the most efficacious approved vaccines commercially available.

“The arrangement upholds our ongoing commitment to fight against such a pandemic of global human importance.”

See also  Sanofi signs $1.45bn deal to acquire Kymab, expanding its immune-therapy pipeline

So far, the Sputnik V Covid vaccine has been registered in 69 countries, covering a total population of more than 3.7 billion people.

The Russian Covid vaccine is said to have 83.1% efficacy against the Delta variant and has shown six times reduction of infection risk. Besides, Sputnik V has also been shown to be 94.4% effective against hospitalizations with 18 times reduction in the risk of getting hospitalized.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This